Comparative effectiveness of biologic disease-modifying antirheumatic drugs and small molecular inhibitors in patients with moderate to severe RA: Prospective observational study

Hanyang University Seoul Hospital0 个研究点目标入组 506 人开始时间: 待定最近更新: 2020年5月18日

适应症

试验速览

暂无简介。

•Patients are included in this study if they are:
•1) 19 years or olders
•2) Patients who satisfy the 1987 American College of Rheumatology (ACR) or 2010 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification criteria for RA
•3) Patients having moderately to severely active RA who are intolerant to csDMARDs including methotrexate and those who have never benn exposed to bDMARDs or small molecular inhibitors before.
•4) Patients who provide written consent to participate in this study

•Patients were excluded from the study if they are:
•1) Patients who are contraindicated to bDMARDs or small molecule inhibitor
•2) Patients who have plans for pregnancy or elective surgery
•3) Patients who had ever diagnosed with any malignancy or are treated for malginancy
•4) Patients who cannot voluntarily provie a written consent to participate in this study
•5) Patients who did not provide a written consent to participate in this study

发起方

Hanyang University Seoul Hospital